Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
10.1161/CIRCULATIONAHA.113.001474 Circulation
About SURPASS-3, SURPASS-5 and the SURPASS Clinical Trial Program SURPASS-3 (NCT03882970) is a 52-week, multi-center, randomized, open-label trial evaluating the efficacy of tirzepatide 5 mg, 10 mg and 15 mg compared to titrated insulin degludec on glycemic control in adults with type 2 diabetes treated with metformin with or without an SGLT-2 inhibitor
Developed with input from GLP-1 clinicians and obesity-specialist dietitians, the app brings key health data into one place so users can spot patterns, build consistent routines and feel more confident managing their treatment, putting practical support inside their pocket
C., Remy, P., Giordana, C., Maltete, D
Both options are FDA-approved GLP-1 medications, which work by mimicking the GLP-1 hormones your body naturally produces
Currently, Sprout Health accepts major credit cards including Visa, Mastercard, American Express, and Discover for automated monthly billing
